The neuroscience Clinical Reference Group (CRG) covers specialised neuroscience services and specialised adult neurosurgery.
Chair: Professor Adrian Williams, Consultant Neurologist, University Hospitals Birmingham NHS Foundation Trust.
Philip White, North
Paul Eldridge, North
Stephen Sturman, Midlands & East
Rodney Laing, Midlands & East
Michael Dilley, London
Kevin O’Neill, London
Paul Grundy, South
Andria Merrison, South
Shelley Jones, Lead Pharmacist
Sarah Vibert, Patient & Public Voice
Nick Rijke, Patient & Public Voice
Nicholas Bungay, Patient & Public Voice
Jacquie Kemp, Lead Commissioner, email@example.com
A key part of the CRG’s work is the delivery of the ‘products’ of commissioning. These are the tools used by the 10 Hub Commissioning Teams to contract services on an annual basis.
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.
The following service specifications fall within the scope of this CRG:
- Neurosurgery (Adult)
- Neurosciences Specialised Neurology (Adult)
- A Diagnostic service for rare neuromuscular disorders (All Ages)
- Neuromyelitis optica service (adults and adolescents)
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies fall within the scope of this CRG:
- Disease Modifying Therapies for Patients with Multiple Sclerosis (MS)
- Intrathecal Baclofen (ITB)
- Vagal Nerve Stimulation for Epilepsy
- Levodopa-Carbidopa Intestinal Gel (LCIG)
- Deep Brain Stimulation (DBS) In Movement Disorders
Not routinely commissioned:
- Amifampridine phosphate for the treatment of Lambert-Easton Myasthenic Syndrome
- Fampridine for multiple sclerosis
- Deep Brain Stimulation for Refractory Epilepsy
Policy statements are brief documents that define the current commissioning position to support service contracting. They are interim documents for use while a full commissioning policy is being developed or until a formal NICE Technology Appraisal Guideline has been published.
The following policy statements fall within the scope of this CRG:
- Amifampridine (Firdapse) for Lambert Easton Myasthenic Syndrome (LEMS)
- Cerebellar Stimulator Implants
- Fampridine for Multiple Sclerosis (MS)
- Flow Diverting Devices for Intracranial Aneurysms
- Deep Brain Stimulation (DBS) for Indications Except Movement Disorders
- Flow diverter / Pipeline Embolization Device (PED) for intracranial aneurysms